Table 4.

Associations between FGF‐23‐P and FGF‐23‐BM and all‐cause mortality

	FGF‐23‐P		FGF‐23‐BM
	HR (95% CI)	P‐value	HR (95% CI)	P‐value
Unadjusted	4.88 (2.25–10.56)	<0.001*	5.11 (2.36–11.05)	<0.001*
Age, sex	4.51 (2.05–9.90)	<0.001*	4.77 (2.16–10.53)	<0.001*
Age, sex, LVEF	3.23 (1.47–7.13)	0.004*	3.14 (1.39–7.133)	0.006*
Age, sex, eGFR	4.04 (1.75–9.29)	0.001*	4.28 (1.87–9.78)	<0.001*
Age, sex, NYHA	3.76 (1.68–8.41)	0.002*	4.29 (1.92–9.56)	<0.001*
Age, sex, NT‐proBNP	4.06 (1.81–9.09)	<0.001*	4.29 (1.90–9.92)	<0.001*
Fully adjusted	2.71 (1.18–6.20)	0.018*	2.80 (1.19–6.57)	0.018*

Risk estimates for FGF‐23‐P and FGF‐23‐BM treated as a categorical variable (stratified by cut‐off levels derived in a healthy population) unadjusted and adjusted for age and sex and additional covariates with respect to all‐cause mortality; n = 145, events = 32. CI, confidence interval; eGFR, estimated glomerular filtration rate; FGF‐23‐P, fibroblast growth factor 23 measured in peripheral blood; FGF‐23‐BM, fibroblast growth factor 23 measured in bone marrow plasma; LVEF, left ventricular ejection fraction; NT‐proBNP, N terminal pro brain natriuretic peptide; NYHA, New York Heart Association heart failure class; HR, hazard ratio.

^* Indicates Bonferroni corrected P‐value (for multiple testing) considered significant P < 0.025 (P < 0.05/2).